Likewise, sodium-glucose cotransporter 2 inhibitors have been found to possess the ability to reduce the thickness of epicardial adipose tissue, enhance glucose uptake within this tissue, diminish the secretion of pro-inflammatory chemokines, promote the cellularization of epicardial adipose tissue, and subsequently mitigate the likelihood of cardiovascular diseases. This evidence concerns the gene SLC5A2 and cardiovascular disorder.